# A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

Source: https://onco.cc/trials/nct07228247/  
OnCo record `nct07228247` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of HMPL-A251 in advanced solid tumours, run by Hutchmed, now recruiting.

## Summary

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors is a phase 1/2 interventional study registered as NCT07228247 by Hutchmed, with 147 participants planned, started 2025-12-16 and due to reach its primary completion in 2028-11-30. Interventions recorded: HMPL-A251.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07228247
- Phase: 1/2
- Setting: A Phase Ⅰ/Ⅱa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HMPL-A251 in Participants With Advanced or Metastatic HER2-Expressing Solid Tumors
- Sponsor: Hutchmed
- Enrolled: 147

## Sources

- ClinicalTrials.gov NCT07228247: https://clinicaltrials.gov/study/NCT07228247

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Hutchmed](https://onco.cc/companies/hutchmed/)

---
JSON: https://onco.cc/api/v1/entities/nct07228247.json